ArticleJournal of the American Heart Association2017
Apolipoprotein A-I Modulates Atherosclerosis Through Lymphatic Vessel-Dependent Mechanisms in Mice.
Article in Journal of the American Heart Association, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 40 citations in OpenAlex.
- Integrated analyses of single-cell transcriptome and mendelian randomization reveal the role of lymphatic endothelial CD74 in the progression of atherosclerosis.Journal of geriatric cardiology : JGC · 2026Article
- Targeting lymphatic dysfunction in atherosclerosis: a state-of-the-art review on potential therapies and future directions.Frontiers in cardiovascular medicine · 2026Review
- Sex-specific lymphatic responses to estrogen shape atherosclerosis in high-risk mice.Frontiers in cardiovascular medicine · 2026Article
- The Level of Apolipoprotein A-I Is Associated with a Prognosis in Patients with Chronic Heart Failure Especially in HFmrEF and HFpEF: A Retrospective Cohort Study.International journal of general medicine · 2025Article
- Platelet extracellular vesicles preserve lymphatic endothelial cell integrity and enhance lymphatic vessel function.Communications biology · 2024Article
- The indicative effects of apolipoproteins on organic erectile dysfunction: bridging Mendelian randomization and case-control study.Frontiers in endocrinology · 2024Article
- Review
- Article
- Lymphatics in Cardiovascular Physiology.Cold Spring Harbor perspectives in medicine · 2022Review
- Review
- The Role of the VEGF Family in Atherosclerosis Development and Its Potential as Treatment Targets.International journal of molecular sciences · 2022Review
- Angiotensin II Induces Cardiac Edema and Hypertrophic Remodeling through Lymphatic-Dependent Mechanisms.Oxidative medicine and cellular longevity · 2022Article
- Platelet proteome dynamics in hibernating 13-lined ground squirrels.Physiological genomics · 2021Article
- Kidney injury-mediated disruption of intestinal lymphatics involves dicarbonyl-modified lipoproteins.Kidney international · 2021Article
- Focus on the Lymphatic Route to Optimize Drug Delivery in Cardiovascular Medicine.Pharmaceutics · 2021Review
- Apolipoprotein-AI and AIBP synergetic anti-inflammation as vascular diseases therapy: the new perspective.Molecular and cellular biochemistry · 2021Review
- Review
- Follicular regulatory helper T cells control the response of regulatory B cells to a high-cholesterol diet.Cardiovascular research · 2021Article
- APOA1: a Protein with Multiple Therapeutic Functions.Current atherosclerosis reports · 2021Review
- Hypercholesterolemia and Lymphatic Defects: The Chicken or the Egg?Frontiers in cardiovascular medicine · 2021Review
Corrections and comments
- Erratum issued
Authors and funding
7 authors at 3 institutions in 2 countries.
Funding
Abstract
backgroundSubcutaneously injected lipid-free apoA-I (apolipoprotein A-I) reduces accumulation of lipid and immune cells within the aortic root of hypercholesterolemic mice without increasing high-density lipoprotein-cholesterol concentrations. Lymphatic vessels are now recognized as prerequisite players in the modulation of cholesterol removal from the artery wall in experimental conditions of plaque regression, and particular attention has been brought to the role of the collecting lymphatic vessels in early atherosclerosis-related lymphatic dysfunction. In the present study, we address whether and how preservation of collecting lymphatic function contributes to the protective effect of apoA-I. METHODS AND
resultsAtherosclerotic
conclusionsAltogether, we bring forward a new pleiotropic role for apoA-I in lymphatic function and unveil new potential therapeutic targets for the prevention and treatment of atherosclerosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.